Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.
2014 ◽
Vol 32
(15_suppl)
◽
pp. 4129-4129
◽
Keyword(s):
Phase Ii
◽